<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27533931</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1674-8301</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of biomedical research</Title><ISOAbbreviation>J Biomed Res</ISOAbbreviation></Journal><ArticleTitle>Human IgG Fc promotes expression, secretion and immunogenicity of enterovirus 71 VP1 protein.</ArticleTitle><Pagination><StartPage>209</StartPage><EndPage>216</EndPage><MedlinePgn>209-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7555/JBR.30.20140157</ELocationID><Abstract><AbstractText>Enterovirus (EV71) can cause severe neurological diseases, but the underlying pathogenesis remains unclear. The capsid protein, viral protein 1 (VP1), plays a critical role in the pathogenicity of EV71. High level expression and secretion of VP1 protein are necessary for structure, function and immunogenicity in its natural conformation. In our previous studies, 5 codon-optimized VP1 DNA vaccines, including wt-VP1, tPA-VP1, VP1-d, VP1-hFc and VP1-mFc, were constructed and analyzed. They expressed VP1 protein, but the levels of secretion and immunogenicity of these VP1 constructs were significantly different (P&lt;0.05). In this study, we further investigated the protein levels of these constructs and determined that all of these constructs expressed VP1 protein. The secretion level was increased by including a tPA leader sequence, which was further increased by fusing human IgG Fc (hFc) to VP1. VP1-hFc demonstrated the most potent immunogenicity in mice. Furthermore, hFc domain could be used to purify VP1-hFc protein for additional studies.</AbstractText><CopyrightInformation>&#xa9; 2016 the Journal of Biomedical Research. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunology, Nanjing Medical University, Nanjing, Jiangsu 210029, China. xiangbangbang@njmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>China-US Vaccine Research Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Biomed Res</MedlineTA><NlmUniqueID>101551157</NlmUniqueID><ISSNLinking>1674-8301</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DNA vaccine</Keyword><Keyword MajorTopicYN="N">VP1</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">human IgG Fc</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword></KeywordList><CoiStatement>CLC number: R511, Document code: A. The authors reported no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27533931</ArticleId><ArticleId IdType="pmc">PMC4885169</ArticleId><ArticleId IdType="doi">10.7555/JBR.30.20140157</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71[J]. Lancet Infect Dis, 2010,10(11):778-790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71[J]. Lancet Neurol, 2010,9(11):1097-1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios G, Oberste MS. Enteroviruses as agents of emerging infectious diseases. J Neurovirol, 2005,11(5):424-433.</Citation><ArticleIdList><ArticleId IdType="pubmed">16287683</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J. Enterovirus 71 infection: a new threat to global public health?[J]. Lancet Neurol, 2008,7(10):868-869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128195</ArticleId><ArticleId IdType="pubmed">18848307</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggertson L. Infectious disease experts monitor outbreaks of enterovirus 71 in Asia[J]. CMAJ, 2012,184(15):E781-E782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3478366</ArticleId><ArticleId IdType="pubmed">22988146</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu KX, Ng MM, Chu JJ. Developments towards antiviral therapies against enterovirus 71[J]. Drug Discov Today, 2010,15(23&#x2013;24):1041-1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108380</ArticleId><ArticleId IdType="pubmed">20974282</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qian Y, Wang S, et al. EV71: an emerging infectious disease vaccine target in the Far East?[J]. Vaccine, 2010,28(20):3516-3521.</Citation><ArticleIdList><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CC, Lau SK, Woo PC, et al. Human enterovirus 71 epidemics: what's next?[J]. Emerg Health Threats J 2013,6:19780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772321</ArticleId><ArticleId IdType="pubmed">24119538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendry E, Hatanaka H, Fry E, et al. The crystal structure of coxsackievirus A9: new insights into the uncoating mechanisms of enteroviruses[J]. Structure, 1999,7(12):1527-1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">10647183</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, et al. Structure determination of enterovirus 71[J]. Acta Crystallogr D Biol Crystallogr, 2012,68(Pt 9):1217-1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489104</ArticleId><ArticleId IdType="pubmed">22948923</ArticleId></ArticleIdList></Reference><Reference><Citation>Man-Li T, Szyporta M, Fang LX, et al. Identification and characterization of a monoclonal antibody recognizing the linear epitope RVADVI on VP1 protein of enterovirus 71[J]. J Med Virol, 2012,84(10):1620-1627.</Citation><ArticleIdList><ArticleId IdType="pubmed">22930511</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang ML, Chiang PS, Chia MY, et al. Cross-reactive neutralizing antibody responses to enterovirus 71 infections in young children: implications for vaccine development[J]. PLoS Negl Trop Dis, 2013,7(2):e2067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3573098</ArticleId><ArticleId IdType="pubmed">23459633</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener TK, Premanand B, Kwang J. Immune responses to baculovirus-displayed enterovirus 71 VP1 antigen[J]. Expert Rev Vaccines, 2013,12(4):357-364.</Citation><ArticleIdList><ArticleId IdType="pubmed">23560917</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Huang Z, Sao C, et al. Oral immunization of mice using Bifidobacterium longum expressing VP1 protein from enterovirus 71[J]. Arch Virol, 2013,158(5):1071-1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">23275129</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu WH, Kuo TC, Lin YT, et al. Molecular epidemiology of enterovirus 71 infection in the central region of taiwan from 2002 to 2012. PLoS One, 2013,8(12):e83711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877097</ArticleId><ArticleId IdType="pubmed">24391812</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JS, Zhao N, Pan H, et al. Patterns of polymorphism and divergence in the VP1 gene of enterovirus 71 circulating in the Asia-Pacific region between 1994 and 2013[J]. J Virol Methods, 2013,193(2):713-728.</Citation><ArticleIdList><ArticleId IdType="pubmed">23933074</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann MG. The canyon hypothesis. Hiding the host cell receptor attachment site on a viral surface from immune surveillance[J]. J Biol Chem, 1989,264(25):14587-14590.</Citation><ArticleIdList><ArticleId IdType="pubmed">2670920</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordey S, Petty TJ, Schibler M, et al. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection[J]. PLoS Pathog, 2012,8(7):e1002826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406088</ArticleId><ArticleId IdType="pubmed">22910880</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann MG, He Y, Kuhn RJ. Picornavirus-receptor interactions[J]. Trends Microbiol, 2002,10(7):324-331.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110211</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, et al. DNA vaccine constructs against enterovirus 71 elicit immune response in mice[J]. Genet Vaccines Ther, 2007,5:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Wang S, Gan W, et al. Expression and immunogenicity of novel subunit enterovirus 71 VP1 antigens[J]. Biochem Biophys Res Commun, 2012,420(4):755-761.</Citation><ArticleIdList><ArticleId IdType="pubmed">22450314</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Z. DNA vaccine[J]. Adv Genet, 2005,54:257-289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7119308</ArticleId><ArticleId IdType="pubmed">16096015</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitarai N, Sneppen K, Pedersen S. Ribosome collisions and translation efficiency: optimization by codon usage and mRNA destabilization[J]. J Mol Biol, 2008,382(1):236-245.</Citation><ArticleIdList><ArticleId IdType="pubmed">18619977</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashok MS, Rangarajan PN. Protective efficacy of a plasmid DNA encoding Japanese encephalitis virus envelope protein fused to tissue plasminogen activator signal sequences: studies in a murine intracerebral virus challenge model[J]. Vaccine, 2002,20(11&#x2013;12):1563-1570.</Citation><ArticleIdList><ArticleId IdType="pubmed">11858863</ArticleId></ArticleIdList></Reference><Reference><Citation>Condon C, Watkins SC, Celluzzi CM, et al. DNA-based immunization by in vivo transfection of dendritic cells[J]. Nat Med, 1996,2(10):1122-1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">8837611</ArticleId></ArticleIdList></Reference><Reference><Citation>You Z, Huang X, Hester J, et al. Targeting dendritic cells to enhance DNA vaccine potency[J]. Cancer Res, 2001,61(9):3704-3711.</Citation><ArticleIdList><ArticleId IdType="pubmed">11325842</ArticleId></ArticleIdList></Reference><Reference><Citation>Allhorn M, Olin AI, Nimmerjahn F, et al. Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis[J]. PLoS One, 2008,3(1):e1413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173940</ArticleId><ArticleId IdType="pubmed">18183294</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha[J]. J Exp Med, 1994,179(4):1109-1118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2191432</ArticleId><ArticleId IdType="pubmed">8145033</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K, Bi Y, Sun K, et al. Suppression of allergic inflammation by allergen-DNA-modified dendritic cells depends on the induction of Foxp3+ Regulatory T cells[J]. Scand J Immunol, 2008,67(2):140-151.</Citation><ArticleIdList><ArticleId IdType="pubmed">18201369</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Z, Pan C, Lu H, et al. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice[J]. Biochem Biophys Res Commun, 2010,398(3):506-512.</Citation><ArticleIdList><ArticleId IdType="pubmed">20599765</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>